2026-05-01 FDA Warning Letter: kadobarofficial.com Cited for Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
TL;DR
In short: FDA issued a Warning Letter to kadobarofficial.com on 2026-05-01 citing: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kadobarofficialcom-729131-05012026
Argus analysis
kadobarofficial.com (MARCS-CMS 729131) received an FDA Warning Letter dated May 1, 2026 from the Center for Tobacco Products. The letter cites: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 5, 2026.
ENDS/vapor letters cite the Family Smoking Prevention and Tobacco Control Act, primarily section 910's premarket review requirement for new tobacco products. FDA has run recurring enforcement sweeps against online retailers selling flavored, unauthorized e-liquid and disposable-vape SKUs that never cleared a Premarket Tobacco Product Application (PMTA).
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same tobacco/ENDS category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER kadobarofficial.com MARCS-CMS 729131 — May 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Reference #: RW2602406 Product: Tobacco Recipient: kadobarofficial.com 9105 E 56th St., Ste J, PMB 103 Indianapolis , IN 46216 United States support@kadobarofficial.com Issuing Office: Center for Tobacco Products United States May 1, 2026 WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://kadobarofficial.com and determined that nicotine pouch products listed there are offered for sale or distribution to customers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act. Generally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)). New Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded FDA has determined that you offer for sale or distribution to customers in the United States a nicotine pouch product that lacks a marketing authorization order: Peach Pineapple Mint Kado Bar Nicotine Pouches – 20Ct. The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing autho…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Tobacco / ENDS warning letter?
- Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has kadobarofficial.com had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for kadobarofficial.com as of 2026-05-05. Argus ingests new FDA enforcement records daily.
- What FDA violations was kadobarofficial.com cited for?
- The FDA Warning Letter to kadobarofficial.com (issuing office: Center for Tobacco Products) cites: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Classification: Tobacco / ENDS.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-05-01 FDA Warning Letter: kadobarofficial.com Cited for Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-kadobarofficial-com-2026-05-01-tobacco
"2026-05-01 FDA Warning Letter: kadobarofficial.com Cited for Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-kadobarofficial-com-2026-05-01-tobacco.
Argus HQ Research. "2026-05-01 FDA Warning Letter: kadobarofficial.com Cited for Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-kadobarofficial-com-2026-05-01-tobacco.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_kadobarofficial_com_2026_05_01_tobacco_2026,
title = {2026-05-01 FDA Warning Letter: kadobarofficial.com Cited for Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-kadobarofficial-com-2026-05-01-tobacco},
note = {Accessed: July 13, 2026}
}